In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Shire, Barr settle Adderall XR litigation; sign three deals

Executive Summary

In a litigation settlement with Shire, Barr Pharmaceuticals' Barr Laboratories division cannot market generic versions of Adderall XR (mixed amphetamine) for attention deficit hyperactivity disorder in the US until April 1, 2009, unless another company launches a generic formulation of the drug.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • Product or Technology Swap
    • Product Purchase
    • R&D and Marketing (Licensing)

Related Companies